Last reviewed · How we verify
CKD-337
At a glance
| Generic name | CKD-337 |
|---|---|
| Also known as | Atorvastatin Calcium Trihydrate + Choline Fenofibrate, CKD-337(Atorvastatin calcium trihydrate 21.70mg+Cholinfe fenofibrate 178.8mg/capsule) |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337 (PHASE1)
- A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 (PHASE1)
- CKD-337(2) Drug-drug Interaction Study (PHASE1)
- CKD-337 Drug Interaction Study (PHASE1)
- A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-337 CI brief — competitive landscape report
- CKD-337 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI